Oral daily and intermittent ibandronate normalize bone turnover and significantly reduce vertebral fracture risk: Results from a large phase III study.

被引：0
|
作者：
Emkey, R
Recker, RR
Stakkestad, JA
Mahoney, P
Schimmer, RC
机构：
[1] Radiant Res, Wyomissing, PA USA
[2] Creighton Univ, Sch Med, Omaha, NE 68178 USA
[3] CECRO AS, Haugesund, Norway
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2003年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [1] Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
    Delmas, PD
    Recker, RR
    Chesnut, CH
    Skag, A
    Stakkestad, JA
    Emkey, R
    Gilbride, J
    Schimmer, RC
    Christiansen, C
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (10) : 792 - 798
  • [2] Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
    P. D. Delmas
    R. R. Recker
    C. H. Chesnut
    A. Skag
    J. A. Stakkestad
    R. Emkey
    J. Gilbride
    R. C. Schimmer
    C. Christiansen
    Osteoporosis International, 2004, 15 : 792 - 798
  • [3] Oral daily and intermittent ibandronate significantly reduce the incidence of new vertebral fractures: Results from a multinational phase III fracture study
    Felsenberg, D
    Lorenc, R
    Hughes, C
    Schimmer, RC
    Wasnich, R
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S71 - S72
  • [4] Significant reduction in vertebral fracture risk: Evidence for the efficacy of daily and intermittent ibandronate from a large phase III study
    Christiansen, C
    Chesnut, CH
    Delmas, PD
    Skag, A
    Recker, RR
    Stakkestad, JA
    Hoiseth, A
    Felsenberg, D
    Gilbride, J
    Schimmer, RC
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 94 - 95
  • [5] Oral daily and intermittent ibandronate normalise bone turnover and significantly reduce the incidence of new vertebral fractures in women with postmenopausal osteoporosis
    Delmas, PD
    Recker, RR
    Stakkestad, JA
    Mahoney, P
    Schimmer, RC
    Emkey, R
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S55 - S56
  • [6] Vertebral fracture risk in osteoporosis significantly reduced by intermittent or daily ibandronate
    Bachmann, GA
    OBSTETRICS AND GYNECOLOGY, 2005, 105 (04): : 72S - 72S
  • [7] Upper gastrointestinal safety profile of oral daily and intermittent ibandronate: Results from a large pivotal phase III study
    Delmas, PD
    Skag, A
    Chesnut, CH
    Stakkestad, JA
    Christiansen, C
    Hoiseth, A
    Benevolenskaya, L
    Recker, R
    Leishman, B
    Mahoney, P
    Schimmer, R
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S15 - S15
  • [8] Oral daily and intermittent ibandronate have a similar safety profile in elderly and younger patients: Results from the BONE study.
    Ettinger, MP
    Skag, A
    Hoiseth, A
    Leishman, B
    Schimmer, RC
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S158 - S158
  • [9] Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: Results from a pivotal phase III study
    Delmas, P
    Recker, R
    Stakkestad, JA
    Chestnut, C
    Hoiseth, A
    Weichselberger, A
    Huss, H
    von Stein, T
    Schimmer, R
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S15 - S15
  • [10] Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study
    Recker R.R.
    Weinstein R.S.
    Chesnut III C.H.
    Schimmer R.C.
    Mahoney P.
    Hughes C.
    Bonvoisin B.
    Meunier P.J.
    Osteoporosis International, 2004, 15 (3) : 231 - 237
12345